公开(公告)号：EP4225753A1

公开(公告)日：2023-08-16

申请号：EP21789678.6

申请日：2021-10-07

申请人： Leukos Biotech, S.L. ,  Fundació Institut de Recerca Contra la Leucèmia Josep Carreras

发明人： CASTRO- PALOMINO LARIA, Julio ,  CAMACHO GÓMEZ, Juan Alberto ,  MUÑOZ RISUEÑO, Ruth ,  CLÉMENT-DEMANGE, Lise

IPC分类号： C07D413/10 ,  C07D413/12 ,  A61K31/455 ,  A61K31/497

公开(公告)号：EP4445901A2

公开(公告)日：2024-10-16

申请号：EP24191411.8

申请日：2021-10-07

申请人： Leukos Biotech, S.L. ,  Fundació Institut de Recerca Contra la Leucèmia Josep Carreras

发明人： CASTRO- PALOMINO LARIA, Julio ,  CAMACHO GÓMEZ, Juan Alberto ,  MUÑOZ RISUEÑO, Ruth ,  CLÉMENT-DEMANGE, Lise

IPC分类号： A61K31/497

摘要： The present invention relates to new compounds of formula (I):

as modulators of serotonin receptor 1B (5-HTR 1B ) also known as 5-hydroxytryptamine receptor 1B (5-HT 1B ). The compounds are of potential utility in the treatment of diseases and conditions mediated by serotonin receptor type 1B (5-HTR 1B ), such as cancer, including blood cancer and solid tumors, respiratory diseases and hepatic disorders.

公开(公告)号：EP4000617A1

公开(公告)日：2022-05-25

申请号：EP20383021.1

申请日：2020-11-23

申请人： Fundació Institut de Recerca Contra la Leucèmia Josep Carreras

发明人： MUÑOZ RISUEÑO, Ruth ,  CORNET MASANA, Josep Maria ,  CARBÓ MARQUÉS, José María

IPC分类号： A61K31/381 ,  A61K31/4535 ,  A61K31/496 ,  A61P35/02

摘要： The present invention relates to a method of treating a warm-blooded animal, especially a human subject, having leukaemia, preferably acute myeloid leukemia (AML), B and T acute lymphoblastic leukemias (B-ALL and T-ALL), or chronic myeloid leukemia (CML), or a lymphoma or a solid tumour, comprising administering to said animal a therapeutically effective amount of a compound having any of the formulae identified throughout the present specification, optionally together or in combination with a conventional compound or compound mixture useful in any of said treatments, in particular a topoisomerase II inhibitor, an antimetabolite, or an antitumor antibiotic, and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential use; and to a pharmaceutical composition and a commercial package comprising said compound.

公开(公告)号：EP3568136A1

公开(公告)日：2019-11-20

申请号：EP18701134.1

申请日：2018-01-15

申请人： Leukos Biotech, S.L.

发明人： MUÑOZ RISUEÑO, Ruth ,  LARA CASTILLO, Mari Carmen ,  ETXABE ALBERDI, Amaia

IPC分类号： A61K31/473 ,  A61K31/4965 ,  A61K31/706 ,  A61K31/7068

公开(公告)号：EP3348266A1

公开(公告)日：2018-07-18

申请号：EP17382015.0

申请日：2017-01-16

申请人： Leukos Biotech, S.L.

发明人： MUÑOZ RISUEÑO, Ruth ,  LARA CASTILLO, Mari Carmen ,  ETXABE ALBERDI, Amaia

IPC分类号： A61K31/473 ,  A61K31/4965 ,  A61K31/706 ,  A61K31/7068

CPC分类号： A61K31/473 ,  A61K31/4965 ,  A61K31/706 ,  A61K31/7068 ,  A61K2300/00

摘要： The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a serotonin receptor (HTR) modulator, e.g. a HTR antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.